Skip to search formSkip to main contentSkip to account menu

LY335979

Known as: LY 335979 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2011
Highly Cited
2011
Tamoxifen is widely prescribed to patients with estrogen receptor-positive breast cancer, and it is a prodrug that requires… 
Highly Cited
2008
Highly Cited
2008
PurposeIn vitro assessment of drug candidates' affinity for multi-drug resistance proteins is of crucial importance for the… 
2008
2008
Highly Cited
2007
Highly Cited
2004
Highly Cited
2004
Using CYP3A4-expressing Caco-2 cell monolayers, we assessed the roles of CYP3A4-mediated metabolism, P-glycoprotein (P-gp… 
2004
2004
PURPOSE Our intention was to (a) to investigate the safety and tolerability of a potent P-glycoprotein modulator, zosuquidar… 
Highly Cited
2003
Highly Cited
2003
Our study examines the ability of LY335979 (Zosuquidar trihydrochloride) to modulate 3 distinct ABC transporters that are… 
2003
2003
Abstract Purpose. To develop a population pharmacokinetic model for doxorubicin and doxorubicinol in the presence of zosuquidar… 
1998
1998
Compound LY335979 is a P-glycoprotein inhibitor currently entering phase I clinical trials for potential reversal of multidrug…